Stitch Fix vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
NASDAQ: SFIX AI-powered personal styling service shipping curated clothing to 3.7M active clients; $2.1B FY2024 revenue with $87M adjusted EBITDA profitability competing with Amazon Personal Shopper for apparel subscription market.
About
Stitch Fix is a San Francisco-based online personal styling service — listed on NASDAQ (NASDAQ: SFIX) — using a combination of data science algorithms and human stylists to curate personalized clothing, accessories, and footwear selections shipped to subscribers in a 'Fix' (a box of 5 items) who try items at home and keep what they want, paying only for what they keep while returning the rest in prepaid packaging. Founded in 2011 by Katrina Lake and generating $2.1 billion in revenue in fiscal year 2024 with $87 million in adjusted EBITDA (the first full-year profitability milestone after pandemic-era losses), Stitch Fix serves 3.7 million active clients in the US and UK with a hybrid human-AI styling model that makes personalized fashion accessible without the time investment of traditional retail browsing.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.